Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Aspect BIS “Awareness” Indication Supported By Three Studies

This article was originally published in The Gray Sheet

Executive Summary

An expanded indication for Aspect Medical's BIS bispectral index anesthesia monitoring technology for "reducing the risk of intraoperative awareness with recall" will be a competitive advantage, although the impact on sales remains undetermined, the firm says

You may also be interested in...



Anesthesia awareness

Bispectral index (BIS)-guided anesthesia with Aspect Medical's BIS Quatro Sensor does not lower the incidence of anesthesia awareness or reduce administration of volatile anesthetic gases compared with end-tidal anesthetic gas (ETAG) anesthesia, according to results of a 2,000-patient randomized study at Washington University, St. Louis, published in the March 13 New England Journal of Medicine. The results appear to contradict those of the 2,503-patient Australian B-Aware study, in which BIS reduced awareness by 82% compared to "standard clinical practice" (1"The Gray Sheet" Nov. 3, 2003, p. 26). "Reliance on BIS technology may provide practitioners with a false sense of security about the reduction in the risk of anesthesia awareness," authors Michael Avidan, et al., warn. Scott Kelley, M.D., Aspect Medical's medical director, maintains that the Washington University study did not show the same benefits of BIS as the earlier B-Aware trial because it used ETAG, instead of standard therapy, as the control. "The ETAG-guided protocol used in the NEJM study instructed the anesthesia professionals to use a certain amount of inhaled anesthetics and audible alarms set at the minimum level. This is not how anesthesia professionals routinely practice," said Kelley. "We would expect that a protocol which provides significant amounts of volatile anesthesia would produce a low incidence of awareness in these patients.

Anesthesia awareness

Bispectral index (BIS)-guided anesthesia with Aspect Medical's BIS Quatro Sensor does not lower the incidence of anesthesia awareness or reduce administration of volatile anesthetic gases compared with end-tidal anesthetic gas (ETAG) anesthesia, according to results of a 2,000-patient randomized study at Washington University, St. Louis, published in the March 13 New England Journal of Medicine. The results appear to contradict those of the 2,503-patient Australian B-Aware study, in which BIS reduced awareness by 82% compared to "standard clinical practice" (1"The Gray Sheet" Nov. 3, 2003, p. 26). "Reliance on BIS technology may provide practitioners with a false sense of security about the reduction in the risk of anesthesia awareness," authors Michael Avidan, et al., warn. Scott Kelley, M.D., Aspect Medical's medical director, maintains that the Washington University study did not show the same benefits of BIS as the earlier B-Aware trial because it used ETAG, instead of standard therapy, as the control. "The ETAG-guided protocol used in the NEJM study instructed the anesthesia professionals to use a certain amount of inhaled anesthetics and audible alarms set at the minimum level. This is not how anesthesia professionals routinely practice," said Kelley. "We would expect that a protocol which provides significant amounts of volatile anesthesia would produce a low incidence of awareness in these patients.

Aspect Medical Eyes Profitability Through BIS Extension, OEM Integration

The recent approval of Aspect Medical's BISx integration technology is a "critical step" in the firm's efforts to "BIS-enable" future patient monitoring systems introduced to the U.S. market, President & CEO Nassib Chamoun told analysts April 22

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT019244

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel